Drug Discovery for Nervous System Disorders (R21) | Apply Online

Opportunity Summary:

The Drug Discovery for Nervous System Disorders (R21) opportunity (Funding Opportunity Number PAR-07-049) is a National Institutes of Health (NIH) discretionary grant program designed to push early-stage, high-potential drug discovery projects forward for disorders of the nervous system. The central aim is to support exploratory and developmental research that identifies, develops, and tests novel compounds before they reach clinical trials, with an emphasis on prevention and treatment. In practical terms, the FOA is geared toward projects that are still at the preclinical stage, where investigators are trying to generate compelling proof-of-concept data, optimize candidate molecules, and demonstrate enough biological activity and feasibility to justify larger follow-on development.

This announcement uses the NIH R21 mechanism, which is intended for exploratory or early development work where the science is promising but may still be relatively unproven or where the project is trying to break new ground. The R21 format generally fits projects that need support to establish feasibility, develop new leads, refine assays, or produce initial preclinical evidence of efficacy or safety. The FOA also notes that it runs in parallel with another announcement of identical scientific scope that uses the R01 mechanism (PAR-07-048), meaning NIH is supporting the same general research area through both a smaller, exploratory pathway (R21) and a more traditional, larger research project pathway (R01). That parallel structure signals that NIH expects projects to vary in maturity: some will be ready for full-scale R01 studies, while others are better suited to the more flexible, early-stage R21 approach.

The scientific scope focuses on drug discovery and development steps that happen prior to human testing. While the brief description does not list specific disease targets, it broadly covers nervous system disorders and supports work aimed at preventing or treating those conditions. Activities commonly associated with this kind of FOA include identifying new therapeutic targets, screening or designing compounds, improving potency or selectivity, characterizing pharmacological activity, and conducting preclinical testing that may include relevant in vitro and in vivo models. The overall intent is to help teams move from an interesting idea or early hit compound toward a more credible, testable candidate suitable for later-stage development.

On funding levels and award numbers, the FOA does not set aside a dedicated pool of money specifically for this program. Instead, awards depend on NIH budget availability and the volume of strong, meritorious applications received. Because proposed projects can differ substantially in scope and cost, NIH anticipates that both the size and duration of awards will vary from one grant to another. The total number of awards and total dollars ultimately committed will be driven by the number of applications submitted, their scientific quality, the requested budgets, and how long each project is proposed to run under the R21 framework.

Eligibility is broad and includes many types of applicant organizations. Eligible applicants listed include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including those with 501(c)(3) status and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses and other for-profit entities), independent school districts, and a range of government entities such as state, county, city or township governments, special district governments, and public housing authorities/Indian housing authorities. Native American tribal governments (federally recognized) and other tribal organizations are included as well. A notable feature is that foreign institutions are explicitly eligible to apply, expanding participation beyond U.S.-based organizations.

The FOA falls under NIH and is associated with multiple CFDA program areas that reflect the broad neuroscience and behavioral health footprint involved in nervous system drug discovery. The CFDA numbers listed include 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), 93.279 (Drug Abuse and Addiction Research Programs), and 93.866 (Aging Research). This mix signals that projects relevant to mental health, substance use, and aging-related neurological conditions could align with the program, as long as the work is centered on discovering and developing novel compounds with preclinical testing for nervous system disorders.

Administrative details indicate there is no cost sharing or matching requirement. The opportunity was posted November 17, 2006, with multiple receipt dates referenced in the full announcement. The record shows a current closing date of January 7, 2010, and an archive date of February 7, 2010, meaning it is no longer an active open opportunity today, but the summary still describes how NIH structured the program and what it sought to fund during its active period. For applicants who needed the complete requirements, NIH provided a full announcement link and centralized support through the NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Research Project Grant (Parent R01)

Previous opportunity: Research on Mild and/or Unilateral Hearing Loss (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 07 049

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 07 049) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 049", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.